Skin Cancer Radiotherapy Institute (SCRI) Announces First on Long Island to Offer a New Non-Surgical Approach to Treating Skin Cancer
Roslyn Heights, NY (PRWEB) March 04, 2014 -- Skin Cancer Radiotherapy Institute (SCRI) announced that they are the first medical practice on Long Island to acquire the Sensus Healthcare SRT-100™, a non-invasive skin cancer treatment system. The SRT-100™ will provide the local patient community with the most effective, non-surgical and pain free therapy to treat non-melanoma skin cancers, such as Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC), which account for the vast majority of all skin cancers.
“The National Skin Cancer Foundation states that 40-50% of people over the age of 65 will develop a form of skin cancer. While the vast majority of these patients will undergo surgical procedures to remove these cancers, a significant subset are not candidates for these procedures. They may be on blood thinners or have very large tumors in difficult to treat areas such as the nose, the scalp or the shins. Furthermore, some may fear surgery or scarring. For these patients, the SRT-100 is a viable option, and may yield a superior cosmetic result,” said Dr. Lance Barazani, M.D., Board-Certified Dermatologists and Associate Director of SCRI. “We are especially proud of our commitment to superb patient care and our ability to accommodate patients.”
Under the leadership of Dr. Barazani is Raymond Herrick, RTT, ARRT and program director of SCRI. Mr Herrick has 19 years experience in radiotherapy. Most recently he was Chief Radiation Therapist at Memorial Sloan-Kettering Cancer Center of Commack.
“Radiotherapy works by targeting cancer cells, which divide much more frequently than normal cells. While normal skin cells heal after radiation injury, the cancerous cells do not have the time to repair themselves between treatments. The SRT-100 is the ideal machine to deliver surface radiation sufficient to destroy skin cancers while allowing the skin to heal, leaving behind a natural and cosmetically acceptable result,” said Mr. Herrick.
Most insurance companies, including Medicare, will cover the cost of the radiotherapy treatment for the appropriate patients. Some may even cover the cost of radiotherapy used to treat other conditions such as keloid scars. Keloids are thick, unsightly and often painful skin scars that may develop after surgical procedures, or even spontaneously. The SRT-100 has been shown to greatly reduce and even prevent the recurrence of keloid scars.
“Radiotherapy with the SRT-100 is very easy on the patient. This painless treatment takes about 90 seconds of exposure, administered 2-3 times a week for about 4-5 weeks, depending on the patient. The tumors gradually shrink and fade away, often with no scarring,” said Mr. Herrick.
“The most important aspect is that my associates and I are all Board-Certified Dermatologists with extensive experience in skin cancer diagnosis and treatment. As experts, we know exactly what choices are available to a particular patient and now, with the SRT-100, we have an even more extensive array of treatment options. But first and foremost is our dedication to excellent patient care. We treat each and every patient with the utmost respect, as if he or she were a member of our own family,” Dr. Barazani concluded.
Lance Barazani, M.D., F.A.A.D, is a board-certified dermatologist and Associate Director of the Skin Cancer Radiotherapy Institute. Raymond Herrick, RTT, ARRT and program director of the Skin Cancer Radiotherapy Institute.
Melissa Chefec, MCPR, LLC: PR for Doctors, http://www.mcprpublicrelations.com, +1 (203) 968-6625, [email protected]
Share this article